CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫效应细胞相关神经毒性综合征的早期神经学指标
英文原题：An Early Neurological Indicator of Immune Effector Cell-Associated Neurotoxicity Syndrome.
查看英文原题
An Early Neurological Indicator of Immune Effector Cell-Associated Neurotoxicity Syndrome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本文报告一名 58 岁女性难治性弥漫性大 B 细胞淋巴瘤（DLBCL）患者接受CAR-T 细胞治疗的病例。输注后患者发生细胞因子释放综合征（CRS），随后缓解。输注后第 5 天出现失语，第 6 天发生意识丧失。脑 MRI 显示内侧颞叶区可能存在高信号。患者被诊断为继发于 CRS 的免疫效应细胞相关神经毒性综合征（ICANS），并接受地塞米松治疗，意识迅速改善。由于 ICANS 在失语出现后才被确诊，CAR-T 治疗后应密切监测患者认知功能。
展开英文摘要原文
We herein report a 58-year-old female patient undergoing chimeric antigen receptor T-cell (CAR-T) therapy for refractory diffuse large B-cell lymphoma (DLBCL). Following the CAR-T infusion, the patient experienced Cytokine Release Syndrome (CRS), which was subsequently remitted.
However, aphasia was observed five days post-infusion, and a loss of consciousness occurred on the sixth day. Brain MRI revealed a possibly high signal intensity in the mesial temporal region.
The patient was diagnosed with immune effector cell-associated neurotoxicity syndrome (ICANS) secondary to CRS and received treatment with dexamethasone, which promptly improved her consciousness. As the diagnosis of ICANS was confirmed following the emergence of aphasia, vigilant cognitive monitoring of cognitive function is crucial in patients following CAR-T therapy.
论文信息
- 作者
- Yorichika Y、Neshige S、Edahiro T、Aoki S、Maruyama H
- 单位
- Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, JPN.
- 文献类型
- 病例报告
- 期刊
- Cureus2024 Mar
- 原文标识
- PubMed 38690494 · DOI 10.7759/cureus.57298
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →